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Introduction
Crohn’s disease (CD) together with ulcerative coli-
tis belongs to the group of disorders known as inflam-
matory bowel diseases (IBD). The etiology of Crohn’s 
disease still remains not fully explained, although the 
changes in the composition and distribution of intes-
tinal microbiome seem to play a crucial role in the 
development and persistence of inflammation in the 
gastrointestinal tract (Kostic et al. 2014; Scarpellini 
et al. 2015). It is still under debate if the changes in the 
microbiome in IBD are a  cause or a consequence of 
inflammation.
Pediatric-onset CD is on the increase worldwide 
(Benchimol et al. 2017; Ng et al. 2017). Many young 
patients present with an extensive and aggressive course 
of the disease, which is a real therapeutic challenge. 
Treatment of CD is a complex, multistage process and 
depends on the type and clinical activity of the ill-
ness. ECCO/ESPGHAN guidelines recommend the 
usage of exclusive enteral nutrition (EEN) as a  first-
line therapy to induce remission in pediatric patients 
with mild to moderate CD (Ruemmele et al. 2014). 
EEN used as induction therapy should last from six 
to eight weeks and is usually based on standard, liq-
uid, polymeric formulas. During this period, any other 
types of food are withdrawn and patients receive liq-
uid diet orally or through a nasogastric tube, which 
covers full caloric and nutritional demand adjusted to 
the patient’s requirements. Maintenance of remission 
can be achieved with thiopurines or methotrexate. This 
therapeutic approach is called conventional therapy.
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A b s t r a c t
The aim of this study was to determine if there are quantitative differences in Candida fungi between pediatric patients with Crohn’s disease 
(before and after exclusive enteral nutrition (EEN), and the biologic therapy with anti-tumor necrosis factor alpha – (IFX)), and healthy 
controls. DNA was isolated from fecal samples and PCR was used to determine the number of fungal cells. Both therapeutic interventions 
resulted in a statistically significant decrease in Pediatric Crohn’s Disease Activity Index. The numbers of Candida decreased during both 
therapeutic intervention but the difference was statistically significant for the IFX intervention only (p = 0.045). Moreover, fungi population 
in both study groups declined during intervention when compared to the control group but the difference was significant before treat-
ment only in the IFX group (p = 0.013). The total distribution of Candida with both IFX and EEN as well as in the control group differed 
significantly (p = 0.01) before treatment only. No correlation between the numbers of Candida and disease activity as well as the following 
biochemical parameters: serum iron concentration, protein or glucose level were found. It cannot be ruled out that, in combination with 
genetic and immunological disorders, fungi can contribute to the initiation of the disease process and perpetuation of active inflammation.
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The biologic therapy with anti-tumor necrosis fac-
tor alpha (anti-TNFα) is recommended for treatment 
of patients with moderate to severe CD who didn’t 
respond to conventional treatment (with thiopurines 
or methotrexate). Infliximab (IFX) is the biologic agent 
used most often as a first-line treatment in the pediatric 
population. Induction doses of 5 mg/kg are given intra-
venously in 0, 2 and 6 weeks mode, followed by mainte-
nance infusions every eight weeks (Hyams et al. 2007).
The majority of IBD therapies are focused on con-
trolling inflammation, but the question of how or 
whether the clinical status of patients is related to the 
microbiome remains unanswered. The human gastro-
intestinal tract contains a wide range of archaea, pro-
karyota, eukaryota and viruses.
As mentioned above, studies are available in the lit-
erature that concern changes in the bacterial flora of 
the human gastrointestinal tract in the course of IBD; 
however, there are few articles describing the study of 
anti-Candida antibodies and methods based on the 
fungi cultures (McKenzie et al. 1990; Standaert-Vitse 
et al. 2006; Standaert-Vitse et al. 2009). Hence, the pri-
mary objective of the present study was to determine if 
there are quantitative differences in Candida fungi (by 
quantitative real-time PCR (qPCR)) between pediatric 
patients with CD and healthy controls. Another aim of 
this study was to compare the quantitative differences in 
Candida fungi in the newly diagnosed CD during EEN 
and those who were qualified for biologic therapy and 
to find out whether these differences correlate with the 
selected biochemical and clinical parameters.
Experimental
Materials and Methods
Patients. We performed a single-center prospec-
tive study to examine the Candida population in CD 
patients hospitalized in University Children’s Hospital 
in Krakow, Poland.
Patients aged 2 to 18 years diagnosed with CD 
according to the revised Porto criteria (Levine et al. 
2014) were enrolled into two study groups.
The study protocol was approved by Jagiellonian 
University Ethics Committee – the decision no. 
122.6120.68.2015. The informed consent was signed 
by patients’ parents or legal guardians and by patients 
themselves if above 16 years of age.
Group 1 consisted of newly diagnosed children, who 
received EEN for the induction of remission. In this 
group, we collected two stool samples: the first one (N1) 
before any therapeutic intervention and the second (N2) 
2 to 4 weeks after completing EEN. In a group 2, there 
were CD patients who failed to respond or stopped 
responding to conventional maintenance treatment 
(with thiopurines or methotrexate) and therefore 
were qualified for biologic therapy. Stool samples were 
collected prior to the first dose of IFX (Remsima®, 
Celltrion Healthcare, Incheon, Korea) (B1) and then 
4 weeks after the 3rd induction dose (B2).
The exclusion criteria comprised the following: 
1) age of patient below two years old or above 18 years 
of age; 2)  treatment with antibiotics (including anti-
mycotic antibiotics) and probiotics during the period 
of 3 months before collecting the stool sample; 3) con-
firmed infections of the gastrointestinal tract; 4) any 
active neoplastic diseases (particularly of the gastroin-
testinal tract); 5) confirmed immunodeficiency.
The control group consisted of healthy children who 
didn’t meet the exclusion criteria. In this group, we col-
lected one stool sample.
Tests. In all CD patients, we routinely checked hema- 
tological and biochemical parameters, collected stool 
samples and calculated the Pediatric Crohn’s Disease 
Activity Index (PCDAI). All these tests were carried out 
at the University Children’s Hospital in Krakow, Poland.
The stool samples were delivered to the Chair of 
Microbiology of the Jagiellonian University Medical 
College in deep-freeze conditions (–70°C).
DNA extraction from the stool samples. The fro-
zen samples were thawed, precisely weighed (about 
0.1 g of stool sample was used) and homogenized in 
0.1 ml of saline. DNA extraction from all samples was 
performed using the Genomic Mini AX Stool Spin Kit 
(A&A Biotechnology, Gdańsk, Poland), according to 
the manufacturer’s recommendations, with our own 
modification (Gosiewski et al. 2014; Salamon et al. 
2018). After lysis of bacterial and fungal cells with 
lysozyme (Sigma-Aldrich, Poznań, Poland) (1 mg/ml) 
and lysostaphin (Sigma-Aldrich, Poznań, Poland) 
(0.1 mg/ml), the samples were incubated at 37°C for 
20 min. Next, 200 μl 75 mM NaOH (Avantor Perfor-
mance Materials, Gliwice, Poland) was added and the 
samples were incubated at 95°C for 10 min. After incu-
bation, the samples were microcentrifuged (12 000 rpm, 
10 min), supernatants were removed, and the pellets 
were resuspended in 500 μl of the buffer supplemented 
with β-mercaptoethanol (Sigma-Aldrich, Poznań, 
Poland). For each sample, lyticase (Sigma-Aldrich, 
Poznań, Poland) was added (0.1 mg/ml). The samples 
were incubated at 37°C for at least 30 min and micro-
centrifuged (12 000 rpm, 10 min). The next steps of 
DNA extraction were carried out according to A&A 
Biotechnology’s procedure.
Quantitative real-time PCR (qPCR). Candida spp. 
in the fecal samples were quantified by qPCR, as 
described by Gosiewski et al. (2014). To detect specific 
DNA sequences, ready-to-use JumpStart TaqReadyMix 
(Sigma-Aldrich, Poznań, Poland) kit, fluorescently 
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FAM dye labelled probe (FAM-5’-TTAACCTAC-
TAAATAGTGCTGCTAGC-3’-BHQ1) and pairs 
of specific primers (Genomed, Warszawa, Poland): 
(F) 5’-TTGGTGGAGTGATTTGTCTGCT-3; (R) 
5’-TCTAAGGGCATCACAGACCTG-3’ (Genomed) 
for Candida were used (Sugita et al. 2012). A standard 
curve was prepared. DNA from the given numbers of 
C. albicans ATCC10231 was added in serial dilutions 
from 101 to 107 cells (in a volume of 1 ml saline ~ 1 g) 
to a  series of qPCRs. The reactions were carried out 
in a CFX96 thermocycler (BioRad, California, USA). 
A standard curve from these data is shown in Fig. 1. 
Detection and quantitation were linear over the range 
of the DNA concentrations examined. To determine 
the number of Candida cells, the fluorescent signals 
detected from DNA of stool samples (in duplicate) in 
the linear range of the assay were averaged and com-
pared to the standard curve.
Statistical analysis. Descriptive statistics were 
calculated for quantitative variables. In the case of 
variables following a normal distribution, means and 
standard deviations were presented. For variables dem-
onstrating distribution other than normal, medians and 
interquartile ranges were used. The Mann-Whitney 
test was used to compare the differences between the 
two study groups and control. The Kruskal-Wallis test 
was applied for comparisons for all study groups. In 
the latter case, multiple comparisons of mean ranks 
for all groups were performed in order to assess the 
differences between pairs of groups. The correlation 
between variables was assessed with Spearman’s rank 
correlation coefficient. Statistical analysis was carried 
out with the Statistica 13.1 (StatSoft, Inc. Tulsa, Okla-
homa, USA) software.
Results
A total of 61 patients were enrolled in this study. 
Table I contains the baseline patient characteristics. The 
control group consisted of eight girls and nine boys, 
aged on average 140.76 months (± 34.58). Both thera-
peutic interventions resulted in a statistically signifi-
cant decrease in disease activity assessed according to 
PCDAI. In group 2, the mean PCDAI was 47.5 points 
(ranged from 5 to 60 points) before induction therapy 
and decreased to a mean of 9.04 (ranged from 0 to 20) 
points (p = 0.00). In group 1, the mean initial PCDAI 
was 32.03 points (ranged from 0 to 65) and dropped to 
a mean of 5.93 (ranged from 0 to 57.5) points (p = 0.00).
The DNA sequences isolated from all 139 fecal 
samples were analyzed using qPCR. The presence of 
Candida DNA was assessed quantitatively by qPCR 
(Fig. 1 and Fig. 2).
The numbers of Candida decreased during the 
therapeutic intervention in both groups (Fig. 2). This 
Fig. 1. A RT-PCR standard curve by plotting the threshold cycle 
(Cq) versus the number of C. albicans ATCC10231 (CFU/g). The 
DNA was amplified with the primers labeled with FAM.
Male:Female, n (%) 7 (54%):6 (46%) 29 (60%):19 (40%) 9 (53%):8 (47%)
Age at diagnosis, months; mean (± SD) 137 (± 48.15) 160.27 (± 37.11) N/A
Age at initial treatment, months; mean (± SD) 157.15 (± 45.16) 160.27 (± 37.11) N/A
Weight, kg; mean (± SD) 41.97 (± 16.3) 40.93 (± 14.05) 42.8 (± 17.2)
Height, cm; mean (± SD) 149.95 (± 20.31) 155.3 (± 19.1) 148.7 (± 18.8)
BMI, kg/m2; mean (± SD) 17.89 (± 3.62) 16.4 (± 2.92) 18.3 (± 3.8)
PCDAI-1; mean (± SD) 47.5 (± 16.43) 32.03 (± 15.01) N/A
PCDAI-2; mean (± SD) 9.04 (± 6.5) 5.93 (± 11.36) N/A
Table I
Baseline patient characteristics.
EEN – exclusive enteral nutrition; N/A – not applicable; PCDAI (Pediatric Crohn’s Disease Activity Index):
1 – prior to therapeutic intervention, 2 – after therapeutic intervention
Characteristics Biologic therapy – IFX(n = 13)
EEN
(n = 48)
Control group
(n = 17)
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difference was statistically significant in group 2 (IFX 
intervention) (p = 0.045) but not in a group  1 (EEN 
intervention) (p = 0.626). Additionally, fungi popula-
tion in both studied groups declined during interven-
tion when compared to the control group but the dif-
ference was significant before treatment only in IFX 
group (p = 0.013) and in the EEN group, it was close to 
statistical significance (p = 0.056) (Fig. 2).
The total distribution of Candida in the large intes-
tine contents before treatment with both IFX and EEN 
as well as in the control group differed significantly 
(p = 0.01). The total fungal distribution after treatment in 
the three groups was statistically insignificant (p = 0.39).
We didn’t find any correlation between the numbers 
of Candida and disease activity as well as with such 
biochemical parameters as serum iron concentration, 
protein or glucose level.
Discussion
The increasing occurrence of Crohn’s disease and 
the decreasing age of patients stimulate researchers 
to find out the causes behind this illness (Benchimol 
et al. 2017; Ng et al. 2017). Although, until now, it has 
not been possible to associate a particular microorgan-
ism with CD etiology, microbial participation is still 
considered crucial, besides genetic and immunological 
disorders, for induction or intensification of inflamma-
tion in the gastrointestinal tract (Gosiewski et al. 2012; 
Wright et al. 2015). However, there is still insufficient 
knowledge concerning the role of fungi in the course 
of CD, as well as the impact of the treatment on gastro-
intestinal colonization with fungi of the genus Candida 
in IBD patients.
Research by Sokol et al. (2017) demonstrated a sig-
nificant increase in the Candida albicans population 
size in patients with IBD in the period of disease exac-
erbation compared to the period of remission and 
healthy people. However, the authors did not analyze 
the influence of the treatment type on the observed 
change in mycobiota. Similar results were obtained 
by Standaert-Vitse et al. (2009) where CD patients 
were more frequently and more heavily colonized by 
C. albicans than the patients in the control group. As 
it was found in our study, the group undergoing bio-
logic therapy showed significantly higher colonization 
with Candida spp. when compared to healthy children 
(Fig. 2). Additionally, the patients qualified for biologic 
therapy exhibited higher numbers of Candida fungal 
cells than the children qualified for nutritional treat-
ment (Table I, Fig. 2); but, the difference between them 
was not statistically significant. It has to be noted that 
the clinical activity of the disease in patients qualified 
for biologic therapy was greater as compared to the 
group treated with EEN. A further difference was the 
disease duration, which was longer in the IFX group. 
It is also telling that these patients stayed longer in the 
hospital for anti-inflammatory and immunosuppressive 
treatment and also, in the past, could have undergone 
antibiotherapy more often. This is an implication that, 
with the increase in the activity of the disease and its 
duration, the numbers of Candida fungi also increased, 
which was also confirmed by Li et al. (2014). Moreo-
ver, the researchers found that in the inflamed colonic 
mucosa Candida fungi were more numerous than in 
non-inflamed areas and that the number of fungal 
cells correlated with overexpression of proinflamma-
tory cytokines, i.e., TNF-α and IFN-γ. It might have 
been the cause behind the loss of tolerance to commen-
sal fungi among the patients with CD, which resulted 
in immune disorders as a consequence of continuous 
induction of an inflammatory response (Li et al. 2014). 
A confirmation of this hypothesis can be the study by 
Iliev et al. (2012), which found that mice with Dectin-1 
deficiency (it’s a receptor responsible for recognition 
of fungal β-glucan) are substantially more susceptible 
to developing intestinal inflammation in comparison 
with mice without the gene knockout encoding this 
receptor. Furthermore, animals with disorders within 
Dectin-1 triggered the release of excessive amounts of 
TNF-α, IFN-γ and IL-17 against fungi within intesti-
nal microbiota, including Candida spp. It is also worth 
noting that administering of antimycotic fluconazole to 
mice resulted in alleviating the symptoms of the disease 
(Iliev et al. 2012). These observations could confirm our 
results, in which the number of Candida, before the 
start of biologic therapy, were significantly higher than 
Fig. 2. Quantitative assessment of fungi of the genus Candida 
using qPCR in the stool of patients with CD before and after bio-
logic (IFX) and exclusive enteral nutrition (EEN) treatments and 
control group.
a – significant differences between children with CD and the control 
group; b – significant differences between children with CD before and 
after biologic treatment.
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two weeks after its completion (p = 0.045) (Fig. 2). The 
strong anti-inflammatory activity of IFX enables the 
healing of the intestinal mucosa, which has probably 
reduced the gastrointestinal colonization with fungi. 
This effect was less visible in the case of EEN treatment 
when the reduction in the number of fungi was on the 
borderline of significance (p = 0.056) (Fig. 2).
Zwolinska-Wcislo et al. (2009) demonstrated, in 
an animal model, similar observations as regards the 
effectiveness of treatment of patients with inflamma-
tory bowel diseases using antifungal agents and a sig-
nificant clinical improvement following treatment with 
fluconazole.
Our research demonstrated that the IFX therapy 
translated into a statistically significant reduction in the 
number of fungi of the genus Candida, which follow-
ing induction therapy was comparable to the number 
of fungi colonizing the gastrointestinal tract in healthy 
children (Fig. 2).
A large number of Candida fungi in newly diagnosed 
patients (EEN group) and those with very high disease 
activity (IFX group) may be the result of a  long-term 
disease process but may also indicate the participation of 
fungi in the pathogenesis of CD. It cannot be ruled out 
that in combination with genetic and immunological 
disorders, fungi can contribute not only to the initiation 
of the disease process but also play a role in maintain-
ing an active inflammation. None of the applied thera-
peutic interventions has a documented direct effect on 
mycobiome. However, both methods of treatment have 
a proven effect on the so-called mucosal healing. It can 
be presumed that the reduction in the number of Can-
dida is an indicator of recovery and improvement of the 
defensive role of the mucosal barrier.
This study provides additional information to the 
multifactorial nature of CD and may contribute to the 
modification of therapeutic approach.
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